Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Clasificación en acciones #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Precio por acción
$207.15
Capitalización bursátil
$366.28B
Cambio (1 día)
0.99%
Cambio (1 año)
2.91%
País
US
Comercio AbbVie Inc. (ABBV)

Categoría

Ratio P/S de AbbVie Inc. (ABBV)
Ratio P/S al March 2026 TTM: 6.35
Según los informes financieros más recientes y el precio de las acciones de AbbVie Inc., el ratio P/S actual (TTM) es 6.35. Al final de 2024, el ratio P/S era 5.58.
Historial del ratio P/S de AbbVie Inc. desde 2009 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
2026 (TTM) 6.35 -5.07%
2025 6.69 19.89%
2024 5.58 10.63%
2023 5.04 2.31%
2022 4.93 15.61%
2021 4.26 9.36%
2020 3.90 -1.07%
2019 3.94 -9.12%
2018 4.34 -20.71%
2017 5.47 38.08%
2016 3.96 -5.93%
2015 4.21 -19.47%
2014 5.23 17.09%
2013 4.47 52.37%
2012 2.93 -9.61%
2011 3.24 -10.35%
2010 3.62 -9.11%
2009 3.98 0.00%
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
14.26 124.49%
US
4.96 -21.89%
GB
6.18 -2.71%
US
5.18 -18.49%
CH
4.40 -30.77%
US